NEW BLOG – Targeted Therapy for Biliary Cancers #biliarycancers #gallbladder #bileduct blog.championsoncology.com/blog/targeted-…
hubs.li/H0GR-T70
Impressive how quickly things are changing for #PrecisionMedicine in #BiliaryCancers ! Congrats to Arndt Vogel for their recent work.
👍🏻More targets (wide NGS panel 🙏)
‼️fFGFR not as frequent as we thought!
(I could not resist to create this slide for my next presentation… 😉)
Just published! Detailed review and great #summary of #secondline #chemo trials in #BiliaryCancers by the team at Fundación Jiménez Díaz 😊
SWOG 1815: CisGemNabPacl NOT superior to CisGem for #BiliaryCancers . No benefit in OS, PFS or ORR. Not changing practice… 🤷🏻♀️
…BUT!!!🔍☝️
1️⃣GBC 🔝 benefit
2️⃣LocAdv 🔝 benefit
… So 🤔
❓ New path to explore (I agree Rachna Shroff, MD, FASCO ): NeoGAP (in GBC)?
#GI23
Thank you to @myesmo for inviting me to summarise the current clinical development status of #Immunotherapy in #HCC and #BiliaryCancers . So proud of all patients and researchers that took #HepatoBiliary malignancies to this ESMO Preceptorship in Immuno-Oncology program!
#ESMOAsia23 continues…
Mini Oral session on #GI included two abstracts in #BiliaryCancers
1️⃣ #Zanidatamab in #Asian population (HERIZON-BTC-01)
2️⃣ #Updated outcomes from Pembrolizumab (KEYNOTE-966)
ESMO - Eur. Oncology #HuichuanSun #RichardFinn
My take home messages 📝
Excellent discussion ASCO #GI21 by Rachna Shroff, MD, FASCO “we hit the target “ in #cholangiocarinoma . Should we profile all #biliarycancers at diagnosis?
She always kills it! Jennifer Knox summarizing a complicated landscape brilliantly. #GI20 ASCO. Plus a shoutout to SWOG Cancer Research Network 1815 for #biliarycancers
From AnnalsSurgOncology: Lymph node status is a strong predictor for recurrence in #BiliaryCancers . A secondary analysis of S0809 estimated survival benefits of adjuvant chemoradiation based on nodal status in this population compared to historic controls. ow.ly/18gQ50MWgXw
‼️Fantastic opportunity not to be missed!
Are you interested in #cholangiocarcinoma and #BiliaryCancers ?
Whatever interest you have (🩺/🔬), apply to the ENSCCA_2020 and Cholangiocarcinoma Foundation Mentorship Program!
➡️Link 👇
➡️Deadline September 2022
cholangiocarcinoma.org/icrn/internati…
Embracing the Era of Individualized Therapy in Advanced #BiliaryCancers . Interesting discussion with Drs. Javle (Milind Javle), Borad, & He (@Ruthhe12) via PeerView. MD Anderson Cancer Center Mayo Clinic Georgetown Lombardi GU Medical Center Cholangiocarcinoma Foundation #GI22
OncoAlert
ABC-06 study The Lancet Oncology
Second-line FOLFOX vs active symptom control in #biliary#cancer. 1st randomized ph-3 #clinicaltrial in this setting. Should FOLFOX be the standard second line for #biliarycancers ❓ thelancet.com/journals/lanon…
Embracing individualized treatment of #biliarycancers ? Join PeerView & Cholangiocarcinoma Foundation in-person @ #GI22 or virtually on 1/21 and get expert insights from Drs. Javle (@JavleMilind), Borad, & He (@Ruthhe12) on bringing precision medicine to #patientcare . bit.ly/Biliary22
Discussion on ABC-06 highlights how amazingly busy the field of #biliarycancers is - goosebumps! Cholangiocarcinoma Foundation SWOG Cancer Research Network NCI Center for Cancer Research #ASCO19 #hpbcsm
We are delighted to welcome Dr Shivan Sivakumar to our Institute! 🎉
He is a leading expert in #Pancreatic , #Liver , & #BiliaryCancers & will strengthen our research & clinical excellence in #Oncology 🔬
➡️bit.ly/3SFeLtA
#CancerResearch #AcademicTwitter
💫Out in The Lancet Oncology ➡️ The #BiliaryCancers BABEL project from the EURO-CHOLANGIO-NET as part of the ENS-CCA lead by chiara braconi
📢Leaflets for chemotherapy were made available in 32 languages covering 208 countries
Full paper 👇👇👇👇👇👇
thelancet.com/journals/lanon…
Provocative thoughts 🤔 using #AI in the era of a huge unmet need of #biomarkers (could be of use for both #HCC and #BiliaryCancers 😉)
BCLC GROUP Jakob Nikolas Kather #juliencalderaro
Guys, this is HUGE!!! Gem/Cis plus Durva is POSITIVE in #biliarycancers !! First regimen to topple the SOC in over a decade! Cholangiocarcinoma Foundation AstraZeneca ENS-CCA Global Cholangiocarcinoma Alliance astrazeneca.com/media-centre/p…
Join Mitesh J. Borad, Milind Javle, & Rachna Shroff, MD, FASCO Friday at the San Francisco Marriott Marquis for a CME/MOC/CC symposium on #BiliaryCancers with PeerView & Cholangiocarcinoma Foundation buff.ly/2TAElSo #GI20 #cholangiocarcinoma
RT Society of Surgical Oncology From AnnalsSurgOncology: Lymph node status is a strong predictor for recurrence in #BiliaryCancers . A secondary analysis of S0809 estimated survival benefits of adjuvant chemoradiation based on nodal status in this population compared to histor…